Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Predictive Oncology Inc. (POAI) Message Board

Predictive Oncology (NASDAQ: POAI) CEO Joins NNW P

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 281
(Total Views: 225)
Posted On: 11/11/2020 3:59:04 PM
Avatar
Posted By: NetworkNewsWire
Predictive Oncology (NASDAQ: POAI) CEO Joins NNW Podcast to Discuss Company’s Prospects; Provides Update on POAI Subsidiaries

- Predictive Oncology CEO Carl Schwartz featured on NNW’s podcast to discuss the company’s prospects
- Schwartz elaborated on company’s various divisions, affirming that POAI had begun to see revenue trends stabilize, cash burn rates decline
- TumorGenesis received overwhelmingly positive feedback on its initial product launches, with plans to extend its technological prowess to address other oncological segments
- Soluble Biotech, which announced its first major contract in August, is expected to reveal news of second order win in near future
- Schwartz touched upon POAI’s Helomics business, stating his belief that division could soon transition towards monetizing its unique and one-of-a-kind asset portfolio

Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz was recently featured in an exclusive audio interview with NetworkNewsWire (“NNW”), a financial news and content distribution company, to provide an update on the company’s recent milestones and near-term goals following the October release of his open letter to Predictive Oncology’s shareholders (https://nnw.fm/GKNld). During the wide-ranging conversation, Schwartz sought to update listeners on the company’s subsidiaries – Skyline Medical, TumorGenesis, Soluble Biotech and Helomics (https://nnw.fm/ATn31).

Schwartz commenced by outlining the status of the company’s Skyline Medical business, charged with overseeing the manufacture and sale of their proprietary STREAMWAY system – designed to provide medical facilities with a direct-to-drain fluid disposal system. The CEO revealed that although the company had sought to reduce emphasis on its legacy division, the company had sold 18 STREAMWAY units thus far in 2020 with the expectation of selling between 5-7 more over the course of the year.

Moreover, he explained that the business was throwing off an estimated $700 thousand in annual free cash-flows—a figure which has proven to be more than sufficient to cover the unit’s operating expenses.

Schwartz went on to elaborate on the TumorGenesis business, which specializes in the field of ovarian cancer, creating laboratory-grown cancer cells which can then be used to assist researchers and clinicians identify which cancer cells bind to specific biomarkers. He revealed that the company had received overwhelmingly positive feedback in regards to the division’s initial product launch and stated that the company would seek to extend its technological prowess towards addressing oncological segments such as lung cancer in the future.

The interview later transitioned to POAI’s most recent acquisition, Soluble Biotech, which seeks to provide optimized FDA-approved formulations for vaccines, antibodies and other protein therapeutics in a faster and lower cost basis to its customers. In August 2020, the company announced its first contract with a major pharmaceutical company for protein expression and solubility studies, and Schwartz stated that a second significant contract would be announced in the near future. Going forward, the CEO expressed his optimism on further contract wins as well as the award of certain grants, which had been applied for by the division.

Schwartz also touched upon Predictive Oncology’s outlook for the fourth quarter – placing particular emphasis on the prospects of the company’s Helomics business. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer case tumors to build AI-driven models of tumor drug response with the hope of improving outcomes for the patients of today and tomorrow. With the wealth of knowledge and experience gleaned over its operational lifespan, Schwartz affirmed his belief that Helomics was well on its way towards monetizing its exceptional and one-of-a-kind asset portfolio and validating the ambitions that POAI had harbored for the division upon its purchase a little over two years ago.

For more information, visit the company’s website at www.Predictive-Oncology.com.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer



(0)
(0)




Predictive Oncology Inc. (POAI) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us